Video from AACC 2019: Carmen Wiley on this week's highlights

Aug 5, 2019
2019 08 05 22 22 5989 Wiley Carmen Aacc 2019 400

ANAHEIM, CA - What are the highlights to see at this week's American Association for Clinical Chemistry (AACC) meeting? LabPulse.com Editor-in-Chief Emily Hayes spoke with AACC 2019 President Carmen Wiley, PhD, about top presentations at the conference, as well as some of the major issues facing clinical chemistry right now.

Carmen Wiley, PhD, 2019 president of the AACC.

Latest in Home
T Cell Social
FDA issues safety warning for risk of T-cell malignancies with CAR T-cell therapies
November 30, 2023
Breast Mammo Social
AI model could prevent unnecessary treatment for breast cancer patients, says study
November 30, 2023
Crispr Cas9 Gene Editing Social
KSQ Therapeutics receives FDA clearance for trial of CRISPR-Cas9 engineered tumor therapy
November 29, 2023
Brain Abstract Social
Potential drug target to prevent small vessel disease identified in study
November 29, 2023
Related Stories
2019 08 05 17 59 6641 Aacc 2019 400
COVID-19
AACC moves annual meeting to December
2019 08 05 17 59 6641 Aacc 2019 400
Molecular Diagnostics
AACC draws nearly 20,000 attendees
2019 08 08 18 01 3923 Zabaleta Eugenio Aacc 2019 400
Home
Video from AACC 2019: How to get physicians to order the right lab test
2019 08 07 20 34 5027 Gruson Damien Aacc 2019 400
Trends and Finance
Video from AACC 2019: What's the future of AI in lab medicine?
More in Home
FDA issues safety warning for risk of T-cell malignancies with CAR T-cell therapies
The FDA issued a safety warning that patients who have received treatment with BCMA- or CD19-directed autologous CAR T-cell immunotherapies may be at higher risk of developing new T-cell malignancies, including CAR-positive lymphoma.
November 30, 2023
T Cell Social
AI model could prevent unnecessary treatment for breast cancer patients, says study
Breast cancer patients could be spared unnecessary chemotherapy with the use of a new artificial intelligence (AI) tool that helps predict survival risk, say researchers.
November 30, 2023
Breast Mammo Social
KSQ Therapeutics receives FDA clearance for trial of CRISPR-Cas9 engineered tumor therapy
Biotech firm KSQ Therapeutics has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a phase I and II trial of KSQ-001EX, KSQ’s CRISPR-Cas9 engineered tumor-infiltrating lymphocyte program.
November 29, 2023
Crispr Cas9 Gene Editing Social
Potential drug target to prevent small vessel disease identified in study
Scientists say lab-grown small blood vessels used in new disease models point to a theoretical potential treatment for a major cause of stroke and vascular dementia.
November 29, 2023
Brain Abstract Social
Candel Therapeutics to lay off 50% of workforce, refocus on advanced oncology immunotherapies
Candel Therapeutics, a biopharmaceutical company focused on developing cancer-fighting immunotherapies, will lay off 50% of its workforce.
November 28, 2023
Business Graph Money Stocks Social
Scipher Medicine, Quest Diagnostics collaborate on RA diagnostics
Scipher Medicine and Quest Diagnostics have announced a multiyear collaboration to expand access to diagnostic services for patients with rheumatoid arthritis (RA).
November 28, 2023
Blood Test Samples Lab Social
Nanopore sequencing slashes tumor analysis times and costs
Nanopore sequencing makes the analysis of copy number variations (CNVs) faster, cheaper, and simpler, according to a preprint paper from researchers at Dartmouth-Hitchcock Medical Center.
November 28, 2023
Dna Sequence Social
AI-powered blood test supports risk stratification of heart disease patients
A blood test powered by artificial intelligence (AI) has shown promise in the assessment of patients with total blockage of a heart artery.
November 27, 2023
Heart Pulmonary Trunk Social
Nasdaq issues delisting notice to T2 Biosystems
T2 Biosystems has received a delisting notice from Nasdaq after failing to satisfy the minimum $35 million market value of listed securities threshold required to remain listed.
November 27, 2023
Stock Exchange Social
Siemens Healthineers contracts with NIAID to develop NGS-based sepsis test
Siemens Healthineers has secured a three-year, $5.5 million contract with the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health, to develop a test to improve sepsis treatment.
November 22, 2023
Sepsis Bacteria Social
Universal DX partners with Quest Diagnostics, closes $70M series B financing round
Liquid biopsy firm Universal DX and Quest Diagnostics have formed a strategic collaboration under which Quest will exclusively offer services for Universal DX’s Signal-C colorectal cancer screening test in the U.S.
November 21, 2023
Colorectal Cancer Social
Bit.bio unveils cell therapy candidate for liver conditions
Synthetic biology company bit.bio has unveiled a lead cell therapy candidate as a treatment for life-threatening liver conditions, and it has set out its broader cell therapy pipeline.
November 22, 2023
Liver Anatomy Social
Page 1 of 100
Next Page